You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Splenic marginal zone lymphoma

Showing 26 - 50 of 6,613
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma (MZL)
  • Chiang Mai, Thailand
    Chiang Mai University
Nov 20, 2023

Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Marginal Zone Lymphoma of Ocular Adnexal Trial in Italy (Doxycycline)

Active, not recruiting
  • Marginal Zone Lymphoma of Ocular Adnexal
  • Messina, Italy
  • +6 more
Nov 4, 2022

Lymphoma Trial in Milan (clarithromycin, oral, high dose)

Completed
  • Lymphoma
  • clarithromycin, oral, high dose
  • Milan, Italy
    Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte
Aug 10, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +18 more
  • Scottsdale, Arizona
  • +1 more
Sep 28, 2020

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

Recruiting
  • Marginal Zone Lymphoma
  • Loncastuximab tesirine 150 µg/Kg
  • Loncastuximab tesirine 75µg/Kg
  • Miami, Florida
    University of Miami
Jul 12, 2022

Marginal Zone Lymphoma Trial in United States (Ibrutinib, Rituximab, Placebo)

Recruiting
  • Marginal Zone Lymphoma
  • Los Angeles, California
  • +12 more
Nov 29, 2022

Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)

Suspended
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Aurora, Colorado
    University of Colorado Hospital
Feb 22, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,

Recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Jul 14, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With

Active, not recruiting
  • Adult Acute Lymphoblastic Leukemia in Remission
  • +46 more
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Feb 10, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
  • Marginal Zone Lymphoma
    • Dijon, France
    • +22 more
    Jan 17, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +6 more
    • (no location specified)
    Apr 12, 2023

    Marginal Zone Lymphoma Trial in Austria, Germany (Copanlisib, Rituximab)

    Recruiting
    • Marginal Zone Lymphoma
    • Wien, Austria
    • +19 more
    Mar 14, 2022

    Marginal Zone Lymphoma Trial in Austria, Italy, Switzerland (Tafasitamab, Acalabrutinib)

    Recruiting
    • Marginal Zone Lymphoma
    • Wien, Austria
    • +9 more
    Jul 13, 2022

    Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and

    Completed
    Has Results
    • Anaplastic Large Cell Lymphoma
    • +12 more
    • Iowa City, Iowa
    • +1 more
    Apr 3, 2020

    Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

    Active, not recruiting
    • Ann Arbor Stage II Follicular Lymphoma
    • +9 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 3, 2022

    Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

    Completed
    • Grade 3a Follicular Lymphoma
    • +9 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 31, 2023

    Revlimid® Capsules General Drug Use-results Surveillance

    Recruiting
    • Lymphoma Nonhodgkin
      • Japan, Japan
        Local Institution
      Jun 22, 2022

      Follicular Lymphoma (Gastric or Duodenal), Marginal Zone Lymphoma (Gastric or Duodenal) Trial in Münster (Radiation Therapy)

      Recruiting
      • Follicular Lymphoma (Gastric or Duodenal)
      • Marginal Zone Lymphoma (Gastric or Duodenal)
      • Radiation Therapy
      • Münster, North Rhine-Westphalia, Germany
        Department of Radiation Oncology
      Dec 1, 2021

      B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

      Recruiting
      • B-cell Lymphoma
      • +5 more
      • Louisville, Kentucky
        Norton Cancer Institute
      Jan 24, 2023